Affordable Preeclampsia Therapeutics.

Lemoine, Elizabeth; Thadhani, Ravi

Lemoine, Elizabeth; Thadhani, Ravi.

Afiliación

Lemoine E; Harvard Medical School, Boston, MA, USA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Thadhani R; Harvard Medical School, Boston, MA, USA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: ravi.thadhani@csmc.edu.

Trends Pharmacol Sci ; 40(2): 85-87, 2019 02.

Article en En | MEDLINE | ID: mdl-30609963

ABSTRACT

ABSTRACT

Preeclampsia is one of the leading causes of maternal and perinatal morbidity and mortality, particularly in resource-limited settings. Treatment options for this devastating condition remain extremely limited. The successful application of RNAi technology to suppress the pathogenic protein soluble FMS-like tyrosine kinase-1 (sFLT1) in a baboon model of preeclampsia portends the development of effective therapies potentially accessible to areas with the greatest burden of disease.

Asunto(s)

Preeclampsia; Femenino; Humanos; Placenta; Embarazo; Interferencia de ARN; Receptor 1 de Factores de Crecimiento Endotelial Vascular

Palabras clave

RNAi; hypertensive disorders of pregnancy; preeclampsia; preeclampsia therapeutics; sFLT1; siRNA

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Preeclampsia Tipo de estudio: Prognostic_studies Límite: Female / Humans / Pregnancy Idioma: En Revista: Trends Pharmacol Sci Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google